70 completed, 9 terminated, 5 withdrawn, 3 unknown. 91 Phase 3, 11 Phase 2.
Follow HIV Infection: new trials by email Literature Review of HIV Infection trials Research Report on HIV Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC) - HIV Infection | Phase 3 | Not yet recruiting | University College, London | 800 | 2026-11-01 | 2026-08-28 |
| Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package - HIV Infection, Sexually Transmitted Infection | Phase 3 | Not yet recruiting | HIV Prevention Trials Network | 400 | 2026-09-01 | 2026-06-22 |
| Effectivity of Protein Purified Derivative Treatment for Anogenital Warts in HIV Patient Injection of protein purified derivative - Anogenital Warts, HIV Infection | Phase 2 / Phase 3 | Unknown | Universitas Padjadjaran | 30 | 2024-09-15 | 2024-09-19 |
| A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) DOR/ISL - HIV Infection | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 641 | 2023-03-17 | 2025-12-17 |
| Next Generation Ingestible Sensors for Medication Adherence Measurement Next-generation Reader and ID-Cap System, Truvada for pre-exposure prophylaxis (PrEP), Biktarvy for antiretroviral therapy (ART) - HIV Infection, Adherence, Medication | Phase 3 | Completed | Brigham and Women's Hospital | 15 | 2023-02-06 | 2024-09-25 |
| B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B HEPLISAV-B, ENGERIX-B - HIV Infection, Hepatitis B | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 638 | 2020-12-14 | 2025-07-20 |
| Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017) DOR/ISL, ART - HIV Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 672 | 2020-02-18 | 2026-02-18 |
| Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF - HIV Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 643 | 2020-02-18 | 2026-03-27 |
| HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine, Saline - AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia | Phase 3 | Completed | AIDS Malignancy Consortium | 535 | 2019-07-31 | 2026-10-28 |
| Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians With HIV (St PETER HIV) Varenicline, Cytisine, Nicotine Replacement Therapy - HIV Infection, Alcohol Use | Phase 2 / Phase 3 | Completed | Boston Medical Center | 400 | 2017-07-19 | 2020-12-17 |
| Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence Trial ART, Atorvastatin, ART, Rosuvastatin, ART, No statin - HIV Infection | Phase 3 | Unknown | Makerere University | 320 | 2017-06-01 | 2017-01-31 |
| ODYSSEY (PENTA 20) Dolutegravir, Standard of Care - HIV Infection | Phase 2 / Phase 3 | Completed | PENTA Foundation | 792 | 2016-09-20 | 2025-07-29 |
| Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children Azithromycin, Placebo - Chronic Lung Disease, HIV Infection | Phase 3 | Completed | London School of Hygiene and Tropical Medicine | 347 | 2016-06-01 | 2019-10-09 |
| Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children DTG +DRV/r, SOC - HIV Infection | Phase 2 / Phase 3 | Completed | PENTA Foundation | 318 | 2016-06-01 | 2021-03-30 |
| Same-day ART Initiation Versus Standard of Care After Positive HIV-test Result in Rural Lesotho Same-day ART initiation, Standard of care - HIV Infection | Phase 3 | Completed | Swiss Tropical & Public Health Institute | 276 | 2016-02-01 | 2019-02-19 |
| Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD) - HIV Infection | Phase 3 | Withdrawn | University of Turin, Italy | 2016-01-01 | 2020-11-06 | |
| Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions imiquimod, fluorouracil, questionnaire administration - Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion | Phase 3 | Completed | AIDS Malignancy Consortium | 91 | 2015-12-28 | 2025-07-23 |
| Calcium and High-dose Vitamin D Supplementation on Bone Mineral Density Among HIV-infected Children and Adolescents High dose vitamin D and calcium, Normal dose vitamin D and calcium - Adverse Bone Health, HIV Infection | Phase 3 | Completed | Chiang Mai University | 200 | 2015-04-01 | 2019-08-08 |
| Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure dolutegravir, lamivudine, Continue current antiretroviral regimen - HIV Infection | Phase 3 | Completed | Babafemi Taiwo | 89 | 2014-12-01 | 2019-10-14 |
| Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions imiquimod, fluorouracil, infrared photocoagulation therapy - Anal Cancer, High-grade Squamous Intraepithelial Lesion | Phase 3 | Completed | AIDS Malignancy Consortium | 4446 | 2014-09-24 | 2024-07-26 |
Showing 20 of 91. Sign in to see all of them.
HIV Infections (91) · Acquired Immunodeficiency Syndrome (11) · Hepatitis B (6) · Infections (6) · Sexually Transmitted Diseases (4) · Hepatitis C (3) · Herpes Genitalis (2) · Inflammation (2) · Squamous Intraepithelial Lesions (2) · Tuberculosis (2) · Alcohol Drinking (1) · Anus Neoplasms (1) · Bone Demineralization, Pathologic (1) · Breast Feeding (1) · Cardiovascular Diseases (1)
Blood-Borne Infections (91) · Communicable Diseases (91) · Genital Diseases (91) · Immune System Diseases (91) · Immunologic Deficiency Syndromes (91) · Lentivirus Infections (91) · RNA Virus Infections (91) · Retroviridae Infections (91) · Sexually Transmitted Diseases, Viral (91) · Urogenital Diseases (91) · Virus Diseases (91) · Sexually Transmitted Diseases (87) · Infections (85) · DNA Virus Infections (11) · Pathological Conditions, Signs and Symptoms (11)
Ritonavir (12) · Lamivudine (9) · efavirenz (9) · Raltegravir Potassium (7) · abacavir (6) · abacavir, lamivudine drug combination (6) · Atazanavir Sulfate (5) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (5) · Tenofovir (5) · Lopinavir (4) · lopinavir-ritonavir drug combination (4) · Darunavir (3) · Emtricitabine (3) · Maraviroc (3) · Racivir (3)
GlaxoSmithKline (8) · Merck Sharp & Dohme LLC (6) · French National Agency for Research on AIDS and Viral Hepatitis (5) · ViiV Healthcare (5) · AIDS Malignancy Consortium (3) · ANRS, Emerging Infectious Diseases (3) · Harvard School of Public Health (HSPH) (3) · Kirby Institute (3) · A.O. Ospedale Papa Giovanni XXIII (2) · Abbott (2) · Assistance Publique - Hôpitaux de Paris (2) · Chiang Mai University (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · PENTA Foundation (2) · University of California, San Francisco (2)
United States (33) · France (14) · Italy (13) · Canada (12) · South Africa (12) · Spain (11) · United Kingdom (11) · Puerto Rico (10) · Argentina (9) · Germany (9) · Thailand (9) · Belgium (7) · Switzerland (7) · Australia (6) · Brazil (6)
Connie Celum, MD, MPH (2) · Franco Maggiolo, MD (2) · Alan Winston, Dr. (1) · Alexandre Manirakiza, MD (1) · Anna Wald, MD, MPH (1) · Anne Goldfeld (1) · Antonio Rivero, MD, PhD (1) · Babafemi Taiwo, MBBS (1) · Calmy Alexandra, Md, PhD (1) · Carla Chibwesha (1)
PMID 20074791, PMID 15090796, PMID 16280696, PMID 17617272, PMID 17631387, PMID 18008230, PMID 18230259, PMID 18669425, PMID 18941533, PMID 18978097, PMID 19032103, PMID 19169140, PMID 19404392, PMID 19682100, PMID 19828532, PMID 19843557, PMID 19952712, PMID 20011596, PMID 20042848, PMID 20089951, PMID 20153888, PMID 20607114, PMID 20936979, PMID 20955629, PMID 21048963, PMID 21126954, PMID 21399681, PMID 21406077, PMID 21447515, PMID 21467701, PMID 21570554, PMID 21732834, PMID 22010913, PMID 22015077, PMID 22075088, PMID 22170543, PMID 22205930, PMID 22223838, PMID 22258265, PMID 22339125, PMID 22745608, PMID 22913681, PMID 23039030, PMID 23061422, PMID 23130818, PMID 23134624, PMID 23152368, PMID 23237982, PMID 23657072, PMID 23731330
2014 (2), 2019 (2), U01CA121947 (2), UM1CA121947 (2), 2009 (1), R01MH065163 (1), U01AA020780 (1), U01AA020797 (1), U01AI068632 (1), U01AI068636 (1), UM1AI068619 (1)